Compare GTN & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | PRTC |
|---|---|---|
| Founded | 1897 | 2015 |
| Country | United States | United States |
| Employees | 9582 | 56 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.5M | 423.3M |
| IPO Year | N/A | N/A |
| Metric | GTN | PRTC |
|---|---|---|
| Price | $4.05 | $17.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 4.7K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.89 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.72 | ★ $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $14.50 |
| 52 Week High | $6.44 | $19.92 |
| Indicator | GTN | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 51.72 |
| Support Level | $3.83 | $16.67 |
| Resistance Level | $4.27 | $18.70 |
| Average True Range (ATR) | 0.15 | 0.76 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 58.43 | 30.55 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.